RIGHTMINDER
29.3.2017 08:02:54 CEST | Business Wire | Press release
With the exponential growth of the aged care industry, cost and care issues are prevalent not only in the UK and Europe but globally. ConnectUs Life Pty Ltd, a specialist care-related services provider has launched RightMinder®, an app that leverages advancements in wearable technology and the increase in availability and use of affordable smartwatches. Coinciding with the release of Android Wear 2.0, RightMinder® caters to the elderly, those in need, pre-teens and Professional Carers. Available in multiple languages and in over 136 countries, RightMinder® delivers a patent-pending solution providing fall detection, first alert monitoring and alerts, GPS location reporting, and multiple first alert carer connections.
RightMinder® has been created to connect ‘wearers’ and ‘carers’. Ben Slater, ConnectUs Life CIO says, ”Our core focus is to ensure wearers maintain meaningful independence with an efficient, yet discreet safety and security alert system. Anyone can use RightMinder® without lock-in contracts, nor do they need expensive custom hardware.” Mr Slater says, “Our First Alert Carers are not only from the family & friends orientated network, but also paid professional Carers too.”
Whilst RightMinder® is specifically designed for Android smartwatches (for wearers), the First Alert and Fall Detection functionality is also available on the mobile phone itself, so anyone can use RightMinder® without requiring a smartwatch. However, RightMinder® strongly recommends using a smartwatch for safety and as a discreet alternative to “the big red emergency button” or pendant. Mr Slater says, “We are extremely encouraged by the acceptance of smartwatch technology amongst our focus groups. Wearers have embraced smartwatch technology when paired with the RightMinder® app. RightMinder® has proven to be very easy to use and manage, despite the underlying complexity of the algorithms utilised.”
RightMinder® wearers are securely connected to one or more carers who can then monitor battery life, location and access fast-touch call buttons. If a Wearer triggers a Fall Detection, or if they send an emergency First Alert, their carers all receive immediate notifications and emails to raise an emergency response. Carers then have the option to locate or call their wearers immediately. Additionally when battery life gets low, notifications are also sent to both wearer and carers.
RightMinder® also extends to people living with disabilities such as MS, dementia, brain trauma, epilepsy and for other high need individuals.
RightMinder® helps reduce the level of dependence on professional operators and on tax funded government assistance.
Contrary to the notion that technology can be complicated, RightMinder® is easy-to-use with a user-friendly interface that has been designed to benefit users who are wearers and carers. Alerting carers is now fast, simple and discreet for any RightMinder® wearer.
The convenience that comes with using the app, in addition to the affordability of the innovative concept, gives independence and empowerment to wearers and comfort to carers like never before, even if wearers and carers live countries apart.
RightMinder® aims for peace of mind without being front of mind.
RightMinder® is available on Google Play Store for Carers and Wearers and coming soon to the Apple App Store (for Carers).
For a full video of the app, please see https://www.youtube.com/watch?v=c2XF2YPabDc .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170328006424/en/
Contact:
RightMinder
Drew Steptoe, Joint MD and CEO.
+61 423 009 082
drew@connectus.life
or
Ben
Slater, Joint MD and CIO.
+61 433 773 585
ben@connectus.life
www.connectus.life
| www.rightminder.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
